{"id":60210,"date":"2026-05-04T09:08:56","date_gmt":"2026-05-04T07:08:56","guid":{"rendered":"https:\/\/www.fyb.de\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/"},"modified":"2026-04-30T15:08:56","modified_gmt":"2026-04-30T13:08:56","slug":"mbiomics-secures-e-30-million-for-microbiome-based-therapeutics","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/","title":{"rendered":"mbiomics secures \u20ac 30 million for microbiome-based therapeutics"},"content":{"rendered":"<p>Munich \u2014 The Munich-based Tech\u00adBio company mbio\u00admics has successfully expan\u00added its Series A finan\u00adcing round to a total of 30 million euros. The company intends to use the capi\u00adtal to drive forward the clini\u00adcal deve\u00adlo\u00adp\u00adment of its lead candi\u00addate and further expand its scalable plat\u00adform for micro\u00adbiome-based thera\u00adpies. Inves\u00adtors include the exis\u00adting inves\u00adtors MIG Fonds and Bayern Kapital.&nbsp;<\/p>\n<p>mbio\u00admics GmbH from Munich\/Neuried has comple\u00adted the third closing of its Series A finan\u00adcing round of 12 million euros, raising a total of 30 million euros.<\/p>\n<p>The company plans to use the addi\u00adtio\u00adnal funds to further expand its precli\u00adni\u00adcal data packa\u00adges in prepa\u00adra\u00adtion for an IND submis\u00adsion and to acce\u00adle\u00adrate GMP deve\u00adlo\u00adp\u00adment and produc\u00adtion. The focus will be on prepa\u00adring the clini\u00adcal trial of the lead candi\u00addate MBX-116, which is to be used as a co-therapy with immune check\u00adpoint inhi\u00adbi\u00adtors in advan\u00adced mela\u00adn\u00adoma. The start of a phase 1b trial is plan\u00adned for&nbsp;2027.&nbsp;<\/p>\n<p><strong>mbio\u00admics deve\u00adlops so-called Live Biothe\u00adra\u00adpeu\u00adtic Products (LBPs)<\/strong> \u2014 oral thera\u00adpeu\u00adtics based on live bacte\u00adrial strains. The aim is to harness the func\u00adtional and meta\u00adbo\u00adlic poten\u00adtial of the gut micro\u00adbiome in a stan\u00addar\u00addi\u00adzed, phar\u00admaceu\u00adti\u00adcal format. While fecal micro\u00adbiota trans\u00adplants have alre\u00adady shown the effi\u00adcacy of micro\u00adbiome-based approa\u00adches, they are conside\u00adred diffi\u00adcult to scale up. This is where mbio\u00admics comes in with a proprie\u00adtary tech\u00adno\u00adlogy plat\u00adform that enables the design, analy\u00adsis and produc\u00adtion of complex micro\u00adbial consortia.&nbsp;<\/p>\n<p>The plat\u00adform combi\u00adnes AI- and machine lear\u00adning-based methods with proprie\u00adtary analy\u00adsis tech\u00adno\u00adlo\u00adgies and scalable co-culti\u00adva\u00adtion and scree\u00adning approa\u00adches. In this way, the company aims to advance the deve\u00adlo\u00adp\u00adment of defi\u00adned micro\u00adbial commu\u00adni\u00adties and use them speci\u00adfi\u00adcally for thera\u00adpeu\u00adtic applications.&nbsp;<\/p>\n<p>\u201cWhile the clini\u00adcal poten\u00adtial of the gut micro\u00adbiome is well unders\u00adtood, the deve\u00adlo\u00adp\u00adment of micro\u00adbiome-based thera\u00adpeu\u00adtics into scalable products has been a signi\u00adfi\u00adcant tech\u00adni\u00adcal chall\u00adenge. At mbio\u00admics, we are solving this problem by buil\u00adding a complete tech\u00adno\u00adlogy stack for the design, analy\u00adsis, scree\u00adning and manu\u00adfac\u00adtu\u00adring of complex micro\u00adbial consor\u00adtia. Our focus is now on brin\u00adging our lead candi\u00addate MBX-116 into clini\u00adcal trials,\u201d says <strong>Dr. Johan\u00adnes B. W\u00f6hr\u00adstein, CEO and Co-Foun\u00adder of mbio\u00admics<\/strong>.<\/p>\n<p>In addi\u00adtion to onco\u00adlogy, mbio\u00admics is working on a broa\u00adder pipe\u00adline of micro\u00adbiome-based thera\u00adpeu\u00adtics. The aim is to address other indi\u00adca\u00adti\u00adons in which the gut micro\u00adbiome plays a central role, inclu\u00adding auto\u00adim\u00admune and neuro\u00adde\u00adge\u00adnera\u00adtive diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Munich \u2014 The Munich-based Tech\u00adBio company mbio\u00admics has successfully expan\u00added its Series A finan\u00adcing round to a total of 30 million euros. The company intends to use the capi\u00adtal to drive forward the clini\u00adcal deve\u00adlo\u00adp\u00adment of its lead candi\u00addate and further expand its scalable plat\u00adform for micro\u00ad\u00adbiome-based thera\u00adpies. Inves\u00adtors include the exis\u00adting inves\u00adtors MIG&nbsp;Fonds&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":60214,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-60210","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>mbiomics secures \u20ac 30 million for microbiome-based therapeutics - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"Munich - The Munich-based TechBio company mbiomics has successfully expanded its Series A financing round to a total of 30 million euros. The company intends to use the capital to drive forward the clinical development of its lead candidate and further expand its scalable platform for microbiome-based therapies. Investors include the existing investors MIG Fonds and Bayern Kapital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"mbiomics secures \u20ac 30 million for microbiome-based therapeutics - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Munich - The Munich-based TechBio company mbiomics has successfully expanded its Series A financing round to a total of 30 million euros. The company intends to use the capital to drive forward the clinical development of its lead candidate and further expand its scalable platform for microbiome-based therapies. Investors include the existing investors MIG Fonds and Bayern Kapital.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T07:08:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-mbiomics.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"282\" \/>\n\t<meta property=\"og:image:height\" content=\"282\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"mbiomics secures \u20ac 30 million for microbiome-based therapeutics\",\"datePublished\":\"2026-05-04T07:08:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/\"},\"wordCount\":377,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/\",\"url\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/\",\"name\":\"mbiomics secures \u20ac 30 million for microbiome-based therapeutics - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png\",\"datePublished\":\"2026-05-04T07:08:56+00:00\",\"description\":\"Munich - The Munich-based TechBio company mbiomics has successfully expanded its Series A financing round to a total of 30 million euros. The company intends to use the capital to drive forward the clinical development of its lead candidate and further expand its scalable platform for microbiome-based therapies. Investors include the existing investors MIG Fonds and Bayern Kapital.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png\",\"width\":620,\"height\":410,\"caption\":\"Team von mbiomics (v.l.n.r.): Kristin Torre Vinuesa, Dr. Johannes B. Woehrstein und Dr. Christopher Weidenmaier \u00a9 mbiomics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"mbiomics secures \u20ac 30 million for microbiome-based therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"mbiomics secures \u20ac 30 million for microbiome-based therapeutics - FYB Financial Yearbook","description":"Munich - The Munich-based TechBio company mbiomics has successfully expanded its Series A financing round to a total of 30 million euros. The company intends to use the capital to drive forward the clinical development of its lead candidate and further expand its scalable platform for microbiome-based therapies. Investors include the existing investors MIG Fonds and Bayern Kapital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"mbiomics secures \u20ac 30 million for microbiome-based therapeutics - FYB Financial Yearbook","og_description":"Munich - The Munich-based TechBio company mbiomics has successfully expanded its Series A financing round to a total of 30 million euros. The company intends to use the capital to drive forward the clinical development of its lead candidate and further expand its scalable platform for microbiome-based therapies. Investors include the existing investors MIG Fonds and Bayern Kapital.","og_url":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2026-05-04T07:08:56+00:00","og_image":[{"width":282,"height":282,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-mbiomics.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"mbiomics secures \u20ac 30 million for microbiome-based therapeutics","datePublished":"2026-05-04T07:08:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/"},"wordCount":377,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/","url":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/","name":"mbiomics secures \u20ac 30 million for microbiome-based therapeutics - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png","datePublished":"2026-05-04T07:08:56+00:00","description":"Munich - The Munich-based TechBio company mbiomics has successfully expanded its Series A financing round to a total of 30 million euros. The company intends to use the capital to drive forward the clinical development of its lead candidate and further expand its scalable platform for microbiome-based therapies. Investors include the existing investors MIG Fonds and Bayern Kapital.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2026\/04\/mbiomics-team-2.png","width":620,"height":410,"caption":"Team von mbiomics (v.l.n.r.): Kristin Torre Vinuesa, Dr. Johannes B. Woehrstein und Dr. Christopher Weidenmaier \u00a9 mbiomics"},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/mbiomics-secures-e-30-million-for-microbiome-based-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"mbiomics secures \u20ac 30 million for microbiome-based therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/60210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=60210"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/60210\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/60214"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=60210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=60210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=60210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}